← back to search

Jurriën M. ten Berg

Brewster Place ·
Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research interests include Antiplatelet Therapy and Cardiovascular Diseases, Acute Myocardial Infarction Research, Atrial Fibrillation Management and Outcomes, and Coronary Interventions and Diagnostics.
h-index
84
citations
50,320
works
685
NIH funding
primary concept
email

Recent publications

Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention
Circulation 2024cited by 74position: middledoi
Coronary Artery Bypass Graft Failure in Women
Journal of the American College of Cardiology 2024cited by 24position: middledoi
Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis
European Heart Journal - Cardiovascular Pharmacotherapy 2024cited by 24position: middledoi
The impact of patient-reported frailty on cardiovascular outcomes in elderly patients after non-ST-acute coronary syndrome
International Journal of Cardiology 2024cited by 10position: lastdoi
TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and multivessel or advanced coronary disease: The transcatheter valve and vessels trial (TCW trial): Design and rationale
American Heart Journal 2024cited by 8position: middledoi
Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up
Circulation 2023cited by 98position: middledoi
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis
Nature Reviews Cardiology 2023cited by 76position: middledoi
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium
Nature Reviews Cardiology 2022cited by 292position: middledoi
Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery
JAMA 2022cited by 84position: middledoi
Diagnostic Performance of CCTA and CT-FFR for the Detection of CAD in TAVR Work-Up
JACC: Cardiovascular Interventions 2022cited by 57position: middledoi
External validation of the GRACE risk score and the risk–treatment paradox in patients with acute coronary syndrome
Open Heart 2022cited by 29position: middledoi
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome
European Heart Journal - Cardiovascular Pharmacotherapy 2022cited by 15position: middledoi
COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction
Heart 2021cited by 43position: middledoi
Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry
Atherosclerosis 2021cited by 40position: middledoi
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial
American Journal of Cardiovascular Drugs 2021cited by 29position: middledoi
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype
Circulation Cardiovascular Interventions 2021cited by 27position: lastdoi
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
New England Journal of Medicine 2020cited by 403position: lastdoi
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial
The Lancet 2020cited by 348position: lastdoi
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
New England Journal of Medicine 2020cited by 337position: lastdoi
Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI
Journal of the American College of Cardiology 2020cited by 207position: middledoi
Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG)
Circulation 2020cited by 66position: lastdoi
Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry
Cardiovascular Diabetology 2020cited by 45position: middledoi
Association of Factor V Leiden With Subsequent Atherothrombotic Events
Circulation 2020cited by 15position: middledoi
A Genotype-Guided Strategy for Oral P2Y <sub>12</sub> Inhibitors in Primary PCI
New England Journal of Medicine 2019cited by 618position: lastdoi
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions 2019cited by 528position: middledoi
Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
JAMA Cardiology 2019cited by 240position: middledoi
Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps
Blood 2019cited by 206position: middledoi
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
European Heart Journal - Cardiovascular Pharmacotherapy 2019cited by 99position: middledoi
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
European Heart Journal 2019cited by 80position: middledoi
Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO‐3 randomized trial
Catheterization and Cardiovascular Interventions 2019cited by 50position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Vera H.M. Deneer · Utrecht University8 papers (2012–2022)Deepak L. Bhatt · Technische Universität Dresden7 papers (2013–2023)Gregory Y.H. Lip · Medical University of Białystok6 papers (2015–2023) · 6 papers (2014–2022)Arnoud W.J. van ’t Hof · Cardiovascular Institute Hospital6 papers (2013–2021)Joyce Peper · St. Antonius Ziekenhuis6 papers (2020–2024)Christopher P. Cannon · Harvard University5 papers (2016–2019) · 5 papers (2013–2021)Thomas O. Bergmeijer · Deventer Ziekenhuis5 papers (2014–2021) · 5 papers (2013–2021)Philippe Gabríel Steg · Mount Sinai Hospital5 papers (2013–2019)Laura M. Willemsen · St. Antonius Ziekenhuis5 papers (2020–2024)Stefan H. Hohnloser · Goethe-Institute United Kingdom4 papers (2016–2019)Pim van der Harst · IHS Markit (United States)4 papers (2019–2021)Folkert W. Asselbergs · The University of Texas Southwestern Medical Center4 papers (2014–2021)Kurt Huber · FWF Austrian Science Fund4 papers (2013–2023)Jonas Oldgren · Uppsala University4 papers (2016–2019)Johannes C. Kelder · Nieuwegein Fonds4 papers (2013–2020)Takeshi Kimura · Uji Hospital4 papers (2016–2019)Udaya S. Tantry · Sinai Hospital3 papers (2013–2022)